Lactic Acid Bacteria with Concomitant IL-17, IL-23 and TNFα- Binding Ability for the Treatment of Inflammatory Bowel Disease

Publisher： Bentham Science Publishers

E-ISSN： 1873-4316|18|4|318-326

ISSN： 1389-2010

Source： Current Pharmaceutical Biotechnology, Vol.18, Iss.4, 2017-05, pp. : 318-326

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting IL-23 and Th17-Cytokines in Inflammatory Bowel Diseases

By  

Current Pharmaceutical Design, Vol. 16, Iss. 33, 2010-11 ,pp. : 3656-3660

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting IL-17 and IL-23 in Immune Mediated Renal Disease

By  

Current Medicinal Chemistry, Vol. 22, Iss. 38, 2015-12 ,pp. : 4341-4365

Bentham Science Publishers

Access to resources Recommend Favorite

The IL23/Th17 Pathway as a Therapeutic Target in Chronic Inflammatory Diseases

By  

Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets - Inflammation & Allergy), Vol. 11, Iss. 2, 2012-04 ,pp. : 159-168

Bentham Science Publishers

Access to resources Recommend Favorite

Aberrant frequency of IL-10-producing B cells and its association with the balance of Treg/Th17 in children with inflammatory bowel disease

By Zhu Xiao-Min   Huang Yi-Min   Fan Jian-Feng   Shi Ying-Zuo  

Die Pharmazie - An International Journal of Pharmaceutical Sciences, Vol. 70, Iss. 10, 2015-10 ,pp. : 656-660

Govi-Verlag

Access to resources Recommend Favorite

Anti-IL-13 in Inflammatory Bowel Disease: From the Bench to the Bedside

By  

Current Drug Targets, Vol. 14, Iss. 12, 2013-11 ,pp. : 1444-1452

Bentham Science Publishers

Access to resources Recommend Favorite